Fennec Pharmaceuticals (FRX) Insider Trading & Ownership C$12.10 -0.40 (-3.20%) As of 07/11/2025 03:05 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesBuy This Stock Fennec Pharmaceuticals (TSE:FRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.20%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)C$361.88KNumber OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)C$725.41K Get FRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Fennec Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FRX Insider Buying and Selling by Quarter Fennec Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/7/2025Chris Anigeron RallisDirectorSell1,119C$11.93C$13,352.697/7/2025Chris Anigeron RallisDirectorSell2,127C$3.22C$6,847.887/3/2025Rostislav Christov RaykovDirectorSell10,000C$11.71C$117,096.006/5/2025Rostislav Christov RaykovDirectorSell10,000C$10.66C$106,586.006/2/2025Robert Christopher AndradeSenior OfficerBuy8,220C$6.99C$57,433.145/19/2025Jeffrey HackmanDirectorBuy15,000C$9.77C$146,580.005/16/2025Rostislav Christov RaykovDirectorSell16,667C$9.49C$158,203.164/11/2025Chris Anigeron RallisDirectorSell1,409C$6.93C$9,764.374/4/2025Rostislav Christov RaykovDirectorSell10,000C$7.46C$74,550.003/5/2025Rostislav Christov RaykovDirectorSell7,569C$9.71C$73,503.54 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/14/2025Chris Anigeron RallisDirectorSell1,186C$9.68C$11,485.702/5/2025Rostislav Christov RaykovDirectorSell2,431C$9.66C$23,476.171/6/2025Rostislav Christov RaykovDirectorSell10,000C$8.76C$87,552.0012/20/2024Rostislav Christov RaykovDirectorBuy25,000C$3.87C$96,840.0012/5/2024Rostislav Christov RaykovDirectorBuy796C$8.52C$6,779.0511/18/2024Robert Christopher AndradeSenior OfficerBuy15,816C$3.43C$54,248.8810/8/2024Chris Anigeron RallisDirectorSell1,406C$6.16C$8,662.0810/2/2024Rostislav Christov RaykovDirectorSell2,431C$6.67C$16,212.349/4/2024Rostislav Christov RaykovDirectorSell2,431C$7.45C$18,115.81 (Data available from 1/1/2013 forward) FRX Insider Trading Activity - Frequently Asked Questions Who is on Fennec Pharmaceuticals' Insider Roster? The list of insiders at Fennec Pharmaceuticals includes Adrian J. Haigh, Chris Anigeron Rallis, Jeffrey Hackman, Khalid Islam, Robert Christopher Andrade, and Rostislav Christov Raykov. Learn more on insiders at FRX. What percentage of Fennec Pharmaceuticals stock is owned by insiders? 16.20% of Fennec Pharmaceuticals stock is owned by insiders. Learn more on FRX's insider holdings. Which Fennec Pharmaceuticals insiders have been buying company stock? The following insiders have purchased FRX shares in the last 24 months: Adrian J. Haigh (C$51,332.82), Jeffrey Hackman (C$146,580.00), Khalid Islam (C$50,000.48), Robert Christopher Andrade (C$111,682.02), and Rostislav Christov Raykov (C$222,539.92). How much insider buying is happening at Fennec Pharmaceuticals? Insiders have purchased a total of 182,339 FRX shares in the last 24 months for a total of C$582,135.24 bought. Which Fennec Pharmaceuticals insiders have been selling company stock? The following insiders have sold FRX shares in the last 24 months: Adrian J. Haigh (C$207,029.47), Chris Anigeron Rallis (C$90,955.74), Robert Christopher Andrade (C$152,345.67), and Rostislav Christov Raykov (C$690,197.05). How much insider selling is happening at Fennec Pharmaceuticals? Insiders have sold a total of 121,761 Fennec Pharmaceuticals shares in the last 24 months for a total of C$1,140,527.93 sold. Fennec Pharmaceuticals Key ExecutivesMr. Rostislav Raykov (Age 48)CEO & Director Compensation: $1.2MMr. Robert C. Andrade (Age 49)Chief Financial Officer Compensation: $817.74kMr. Adrian J. Haigh (Age 65)Chief Operating Officer Compensation: $886.92kMr. Mark GowlandControllerMr. Lei FangPresident of Pharstat Inc More Insider Trading Tools from MarketBeat Related Companies SLS Insider Buying CRDL Insider Buying APM Insider Buying GXE Insider Buying MDNA Insider Buying CGC Insider Buying RGC Insider Buying ASND Insider Buying NBY Insider Buying PBM Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Do They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield WatchlistInsider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold? This page (TSE:FRX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
